A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
- 1 January 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 32 (2), 119-135
- https://doi.org/10.2165/00002018-200932020-00005
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Nicotine receptor partial agonists for smoking cessationPublished by Wiley ,2008
- The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurrent Medical Research and Opinion, 2008
- Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illnessAddiction, 2007
- Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersClinical Therapeutics, 2007
- A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokersClinical Therapeutics, 2007
- A double-blind study evaluating the long-term safety of varenicline for smoking cessationCurrent Medical Research and Opinion, 2007
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Outcome criteria in smoking cessation trials: proposal for a common standardAddiction, 2005
- Advances in pharmacotherapy for tobacco dependenceEmerging Drugs, 2004